CTLA4 and neoplasm: Recent clinical trials in patients with advanced melanoma and lung cancer confirm the remarkable potential of immune checkpoint blockade, including anti‐CTLA‐4 and anti‐PD‐1, to enhance effective anti‐tumor immunity and to improve survival in a proportion of the patients (Hodi et al, 2010; Topalian et al, 2012, 1).